Posts Tagged ‘RPRX’

RPRX jumps, GE busy, WSTL steps back

Thursday, January 20th, 2011

Repros Therapeutics Inc. (Nasdaq: RPRX) moved 13.8 percent higher Thursday to $3.13. Volume of 851,490 shares was catching up on its full-day average of 864,758. RPRX’s Androxal drug, meant to treat men with low testosterone, is in clinical trials this month.

General Electric Company (NYSE: GE) was a volume leader Thursday, dealing in 39,598,546 shares, still shy of its full-day average of 54,691,800. Share prices regained 1.2 percent to $18.55.

Westell Technologies Inc. (Nasdaq: WSTL) shares stumbled 15 percent to $3.00. Volume was 1,212,492 shares, triple its daily average, on word that its quarterly income edged up 7 percent.

GKK grand, INTC in the chips, RPRX gets stung

Wednesday, December 1st, 2010

Gramercy Capital Corp. (NYSE: GKK) gained 12.09 percent to close Wednesday at $2.04. Volume of 431,895 shares was slightly less than average.

Intel Corp. (NasdaqGS: INTC) traded Wednesday in 52,197,726 shares, less than its daily share average of 62,444,600. Shares nudged up 1.52 percent to $21.48. INTC 52-week price peak is around $24.37

Repros Therapeutics Inc. (NasdaqCM: RPRX) took a licking by Wednesday’s close, losing 12.16 percent to $1.30, on volume of 221,792, slightly higher than daily average of 160,083. RPRX focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.